Cytokinetics is committed to supporting patients with MYQORZO & You™, a personalized program for patients prescribed MYQORZO ...
Positive results support the potential for Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescent oHCM “The SCOUT-HCM study is important for patients and the field of ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...
A team of scientists has uncovered a critical mechanism that could pave the way for safer and more effective obesity ...
Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without angiotensin-converting enzyme inhibitor use started within 5 years before ...
Figure 1: Enhancement of α–Gal A in lymphoblasts from patients with Fabry disease. Figure 2: Effect of DGJ on expression of α–Gal A in normal and mutant cells. To evaluate intracellular transport of ...
If severe DNA damage is not repaired, the consequences for the health of cells and tissues are dramatic. A study led by ...
News Medical on MSN
Brain-specific enzyme drives branching and extension of O-mannose glycans
Gifu University scientists have uncovered how a brain-specific enzyme reshapes protein-linked sugar chains to facilitate the formation of complex glycans essential for normal brain function. These ...
Levi Garraway, Roche's chief medical officer and head of global product development. Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results